SCHEMBL13322709

SCHEMBL13322709

CNc1cnccc1N1CCC2(CCCNC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 4/20 0.55
▸ CDC42BPB Q9Y5S2 4/20 0.55
▸ ROCK2 O75116 3/20 0.55
▸ CDC42BPA Q5VT25 2/20 0.55
▸ ALDH1A1 P00352 5/20 0.45
▸ CYP3A4 P08684 4/20 0.45
▸ HSD17B10 Q99714 4/20 0.45
▸ CYP1A2 P05177 4/20 0.45
▸ CYP2D6 P10635 4/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HPGD P15428 2/20 0.44
▸ ATR Q13535 1/20 0.44
▸ CYP11B1 P15538 1/20 0.44
▸ USP2 O75604 3/20 0.43
▸ MAPK1 P28482 3/20 0.40
▸ TP53 P04637 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CHEK1 O14757 2/20 0.40
▸ GSK3B P49841 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13322711 0.93 ROCK1 (0.54) ROCK1CDC42BPBROCK2CDC42BPAALDH1A1
SCHEMBL13322708 0.89 ROCK1 (0.43) ROCK1CDC42BPBROCK2CDC42BPAATR
SCHEMBL13322704 0.85 DRD2 (0.46) ROCK1CDC42BPBROCK2CDC42BPAALDH1A1
SCHEMBL13322697 0.83 ROCK1 (0.52) ROCK1CDC42BPBROCK2CDC42BPAALDH1A1
SCHEMBL14328394 0.82 ALDH1A1 (0.53) ROCK1CDC42BPBROCK2CDC42BPAALDH1A1
SCHEMBL14206520 0.81 ROCK2 (0.55) ROCK1CDC42BPBROCK2CDC42BPAALDH1A1
SCHEMBL11888062 0.79 CHRNB2 (0.51) ROCK1CDC42BPBROCK2CHEK1PIM1
SCHEMBL13062559 0.79 PIM1 (0.53) ROCK1CDC42BPBROCK2ATRCHEK1
SCHEMBL13322703 0.77 CHRNB2 (0.43) ROCK1CDC42BPBROCK2ALDH1A1CYP3A4
SCHEMBL13322700 0.76 ALDH1A1 (0.45) ROCK1CDC42BPBROCK2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 — — US disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 — — US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 — — US disclosed
US-8318735-B2 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-11-27 — — US disclosed
US-8318735-B2 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-11-27 — — US disclosed
US-20100130465-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME LLC 2010-05-27 — — US disclosed
US-20100130465-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MERCK SHARP & DOHME LLC 2010-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130465-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS MAPK15, CDK15, MAP3K15 ROCK1 1328/4885CDC42BPB 1072/4885ROCK2 794/4885
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 ROCK1 958/4885CDC42BPB 2436/4885ROCK2 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback